Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Clin Cancer Res. 2011 Dec 5;18(3):869–881. doi: 10.1158/1078-0432.CCR-11-2188

Figure 3. Endoglin is expressed in persistent ovarian tumor and ovarian cancer cell lines and its downregulation leads to decreased cell viability.<.

Figure 3

Figure 3

A) Matched primary/persistent ovarian tumor pairs (n = 12) were subjected to immunohistochemical analysis of endoglin to evaluate changes in expression. Persistent tumors were found to have a higher density of endoglin staining compared to primary specimens. Representative histologic sections are shown for a matched pair (black bar = 100 μm). B) mRNA expression of endoglin was quantified in 8 different ovarian cancer cell lines using quantitative PCR. Gene expression is shown as log2 transformed ΔCT values (difference between the CT value of the gene of interest (endoglin) and that of the housekeeping gene (RPLP0)). C) Downregulation of endoglin in ES2 and HeyA8MDR cells using 2 different siRNA constructs was determined by Western blot analysis. βactin was used as a loading control. D) ES2 and HeyA8MDR cells transiently transfected with anti-endoglin siRNAs had decreased viability as determined by MTT assay. E) Cell cycle analysis (PI staining) revealed that downregulation of endoglin led to an accumulation of both ES2 and HeyA8MDR cells in the sub-G0 or apoptotic fraction. Data are representative of 3 independent experiments. *P<0.001.

HHS Vulnerability Disclosure